Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy.
Department of Pharmacy and Biotechnology (FaBiT), Molecular Diagnostic Unit AUSL ofBologna, University of Bologna, Bologna, Italy.
Future Oncol. 2018 Jul;14(16):1559-1567. doi: 10.2217/fon-2017-0634. Epub 2018 Jun 25.
To evaluate relevance of clinical and molecular factors in adult low-grade gliomas (LGG) and to correlate with survival.
We reviewed records from adult LGG patients from 1991 to 2015 who received surgery and had sufficient tissue to molecular biomarkers characterization.
213 consecutive LGG patients were included: 17.4% were low-risk, according to Radiation Therapy Oncology Group (RTOG) risk assessment. IDH 1/2 mutation, 1p/19q co-deletion, MGMT methylation were found in 93, 50.8 and 65.3% of patients. Median follow-up was 98.3 months. In univariate analysis, overall survival was influenced by extent of resection (p = 0.011), IDH mutation (p < 0.001), 1p/19q co-deletion (p = 0.015) and MGMT methylation (p = 0.013). In multivariate analysis, RTOG clinical risk (p = 0.006), IDH mutation (p < 0.001) and 1p/19q co-deletion (p = 0.035) correlated with overall survival. RTOG clinical risk (p = 0.006), IDH mutation (p < 0.001) and 1p/19q co-deletion (p = 0.035) correlated with overall survival.
Both clinical and molecular factors are essential to determine prognosis and treatment strategies.
评估成人低级别胶质瘤（LGG）临床和分子因素的相关性，并与生存相关联。
我们回顾了 1991 年至 2015 年接受手术且有足够组织进行分子生物标志物特征分析的成人 LGG 患者的记录。
共纳入 213 例连续的 LGG 患者：根据放射治疗肿瘤学组（RTOG）风险评估，17.4%为低危。93%、50.8%和 65.3%的患者存在 IDH1/2 突变、1p/19q 共缺失和 MGMT 甲基化。中位随访时间为 98.3 个月。在单因素分析中，总生存率受肿瘤切除范围（p=0.011）、IDH 突变（p<0.001）、1p/19q 共缺失（p=0.015）和 MGMT 甲基化（p=0.013）的影响。多因素分析显示，RTOG 临床风险（p=0.006）、IDH 突变（p<0.001）和 1p/19q 共缺失（p=0.035）与总生存率相关。RTOG 临床风险（p=0.006）、IDH 突变（p<0.001）和 1p/19q 共缺失（p=0.035）与总生存率相关。
临床和分子因素都是确定预后和治疗策略的重要因素。
